SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/beam-therapeutics-ceo-sold-over-30000-company-shares-heres-what-means-investors","as_of":"2026-04-11T15:08:00.060011+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/11/beam-therapeutics-ceo-sold-over-30-000-company-shares-here-s-what-this-means-for-investors/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/beam-therapeutics-ceo-sold-over-30000-company-shares-heres-what-means-investors","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_d093ca5feb454121","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/11/beam-therapeutics-ceo-sold-over-30-000-company-shares-here-s-what-this-means-for-investors/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-11T22:20:38.427843+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsCEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026.","fetched_title":"Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. | Nasdaq","final_url":"https://www.nasdaq.com/articles/beam-therapeutics-ceo-sold-over-30000-company-shares-heres-what-means-investors","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/beam-therapeutics-ceo-sold-over-30000-company-shares-heres-what-means-investors","source_event_id":"evt_e1ecd2727e83","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"0bc494516a33911c","kind":"unusual_volume","published_at":"2026-04-11T13:40:03+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["April 1, 2026","April 10, 2026","2025","2024","December 17, 2004","April 15, 2005"],"entities":[{"asset_class":"equity","name":"Beam Therapeutics","relevance":"high","symbol":"BEAM","type":"company"},{"asset_class":"person","name":"John Evans","relevance":"high","symbol":"","type":"person"},{"asset_class":"trust","name":"John M. Evans, III 2018 Irrevocable Trust","relevance":"medium","symbol":"","type":"entity"}],"event_type":"other","information_gaps":["No baseline trading volume data is provided in the text, so the 'unusual volume delta' (volume ratio vs average) cannot be computed.","The article does not provide a direct comparison of this sale\u2019s size to a specific volume metric; it only compares sale share counts to Evans\u2019 prior sell-only transactions.","The catalyst hypothesis is presented as the article\u2019s interpretation; the text does not provide independent confirmation beyond the Rule 10b5-1/tax-withholding explanation.","unusual_volume_delta_fields_unavailable_due_to_missing_volume_data: baseline_volume null, volume_ratio null, direction null","catalyst_hint_unconfirmed: article suggests tax/vesting and routine plan; no explicit confirmation beyond that narrative."],"key_facts":["CEO John Evans sold 30,078 Beam Therapeutics shares on April 1, 2026.","The transaction value was approximately $739,000 (per SEC Form 4 filing, per article).","The sale represented 2.5% of Evans\u2019 direct holdings (per article).","Only direct shares were disposed; indirect holdings (~103,000 shares via John M. Evans, III 2018 Irrevocable Trust) were unaffected (per article).","The sale was executed under a pre-established Rule 10b5-1 trading plan (per article).","The article states the sale price was about $24.58 per share (SEC Form 4 reported price) and compares it to an April 1, 2026 closing price of $24.22 (per article).","The article states Evans retained 1,047,205 direct shares and 103,000 indirect shares after the transaction (per article).","The article claims the sale was to cover tax withholding obligations related to vesting of restricted stock units (per article)."],"numeric_claims":[{"label":"shares_sold","value":"30,078"},{"label":"transaction_value_usd","value":"~739,000"},{"label":"percent_of_direct_holdings","value":"2.5%"},{"label":"direct_shares_retained","value":"1,047,205"},{"label":"indirect_shares_held","value":"103,000"},{"label":"reported_sale_price_usd","value":"~24.58"},{"label":"april_1_2026_close_usd","value":"~24.22"},{"label":"april_10_2026_close_usd","value":"~27.43"},{"label":"indirect_shares_approx","value":"~103,000"}],"primary_claim":"On April 1, 2026, Beam Therapeutics CEO John Evans sold 30,078 shares for approximately $739,000 under a Rule 10b5-1 plan, while his indirect trust holdings were unaffected.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Beam Therapeutics CEO John Evans sold 30,078 shares on April 1, 2026 for about $739,000, under a Rule 10b5-1 plan. The article frames the sale as routine (tax/vesting-related) and notes it did not affect his indirect holdings.","topics":["insider trading","SEC Form 4","Rule 10b5-1","share sale","tax withholding","clinical-stage biotech","Beam-101/risto-cel","sickle cell disease"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsCEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026.","tickers":[],"title":"Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.","url":"https://www.fool.com/coverage/filings/2026/04/11/beam-therapeutics-ceo-sold-over-30-000-company-shares-here-s-what-this-means-for-investors/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_75c07cb10fdc in signals